Vesting Linked To Improvement of Shareholder Value
QUEBEC CITY, Sept. 17,
2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR)(TCQX: DGCRF)
(the "Corporation") reports the granting, as of today, of 500,000
options to Richard Bordeleau who was
appointed Senior Advisor to the Board on September 1st, 2013. The vesting of
these options is tied to the delivery of measurable milestones of
which twenty percent can be vested during Mr. Bordeleau's mandate
as Senior Advisor. The options granted will vest in several
installments which are all linked to strong value-creating
milestones. The other options reported on SEDI are tied to several
stringent vesting conditions, which include the possibility that
Mr. Bordeleau be entrusted with other significant
responsibilities. If any of the milestones do not materialize, then
the options related to this condition will not vest.
"We are granting these options to Mr. Bordeleau
because we strongly believe that his contribution to DiagnoCure
will create value for our shareholders. The vesting will occur as
Mr. Bordeleau fulfills his critical mandates, notably by
implementing short-term initiatives and developing mid- to
long-term opportunities" stated Dr. Yves
Fradet, Chairman of the Board and President and Chief
Medical Officer.
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life
sciences corporation that develops and commercializes high-value
cancer diagnostic tests that increase clinician and patient
confidence in making critical treatment decisions. In 2008, the
Corporation launched a colorectal cancer staging test through its
U.S. CLIA laboratory. PrevistageTM GCC is currently
available for licensing. The Corporation has granted a worldwide
exclusive license on the diagnostic applications of its proprietary
molecular biomarker PCA3 to Gen-Probe, now a wholly-owned
subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3
prostate cancer test is commercialized in Europe under CE mark and is approved for
commercialization in Canada and
the United States. For more
information, please visit www.diagnocure.com.
Forward‐looking statements
This release may contain forward‐looking
statements that involve known and unknown risks, uncertainties and
assumptions that may cause actual results to differ materially from
those expected. Forward-looking statements can be identified by the
use of the conditional or forward-looking terminology such as
"anticipates", "assumes", "believes", "estimates", "expects",
"intend", "may", "plans", "projects", "should", "will", or the
negative thereof or other variations thereon. Forward-looking
statements also include any other statements that do not refer to
historical facts. All such forward-looking statements are made
pursuant to the "safe-harbour" provisions of applicable Canadian
securities laws. By their very nature, forward‐looking statements
are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond
DiagnoCure's control. Forward-looking statements are presented for
the purpose of assisting investors and others in understanding
certain key elements of the Corporation's current objectives,
strategic priorities, expectations and plans, and in obtaining a
better understanding of the Corporation's business and anticipated
operating environment. Readers are cautioned that such information
may not be appropriate for other purposes and that they should not
place undue reliance on these forward‐looking statements. For
instance, any forward-looking statements regarding the outcome of
research and development projects, clinical studies and future
revenues, including those related to PROGENSA® PCA3, are based on
management expectations and such outcome may vary materially
depending on global political and economic conditions, dependence
on collaboration partners, uncertainty of healthcare reimbursement,
and marketing and distribution challenges. In addition, the reader
is referred to the applicable general risks and uncertainties
described in DiagnoCure's most recent Annual Information Form under
the heading "Risk Factors". DiagnoCure undertakes no obligation to
publicly update or revise any forward‐looking statements contained
herein unless required by the applicable securities laws and
regulations.
SOURCE DiagnoCure inc.